RPCI I 225612: A Phase II Study of Single Agent Topoisomerase – I inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR – 102), in Patients with Relapsed Small Cell Lung Cancer

A Phase II Study of Single Agent Topoisomerase – I inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR – 102), in Patients with Relapsed Small Cell Lung Cancer

RPCI I 225612
Cancer
Peter Bushunow, MD
Enrolling
Rachel O'Loughlin, RN
(585) 747-4555
(585) 922 - 5665